In the laboratory, many mono-or pan-CDK inhibitors have been reported to display robust anti-tumor effects either by down-regulating MYCN protein or shutting down its transcriptional activity in neuroblastoma (THZ1, CYC065 and dinaciclib) or other cancers (SY-1365, BAY1143572)[24]. Here, MYCN is linked to neuroblastoma.